glycyrrhizic acid has been researched along with Pneumonia, Viral in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, X; Jiang, Y; Liu, C; Qu, F; Xi, H; Zhao, X; Zhao, Y | 1 |
| Li, J; Liu, D; Luo, P | 1 |
| Bai, C; Chang, H; Guo, R; Leung, E; Li, P; Liu, H; Liu, T; Wang, J; Wang, Y; Wu, S; Yang, R; Zhang, X | 1 |
| Bailly, C; Vergoten, G | 1 |
| Chen, JX; Chen, XX; Li, YL; Ma, YJ; Ning, ZY; Qi, WB; Wang, GC; Zhou, HX | 1 |
2 review(s) available for glycyrrhizic acid and Pneumonia, Viral
| Article | Year |
|---|---|
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Metabolism; Betacoronavirus; Cardiovascular Physiological Phenomena; Chloroquine; Congenital Abnormalities; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Susceptibility; Drug Combinations; Drug Delivery Systems; Female; Functional Residual Capacity; Glycyrrhizic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Interferon Type I; Lopinavir; Metformin; Nanoparticles; Oxygen Consumption; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prognosis; Respiratory Physiological Phenomena; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Stillbirth; Ventilation-Perfusion Ratio | 2020 |
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
Topics: Alarmins; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Glycyrrhizic Acid; Humans; Hydroxychloroquine; Membrane Microdomains; Molecular Docking Simulation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Tenofovir | 2020 |
3 other study(ies) available for glycyrrhizic acid and Pneumonia, Viral
| Article | Year |
|---|---|
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Glycyrrhizic Acid; Humans; Interferons; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Reactive Oxygen Species; SARS-CoV-2; Virus Attachment; Virus Internalization | 2020 |
Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.
Topics: Animals; Anti-Inflammatory Agents; Betacoronavirus; Cells, Cultured; Computer Simulation; Coronavirus Infections; COVID-19; Drugs, Chinese Herbal; Gene Expression; Glycyrrhizic Acid; Humans; Interleukin-6; Lipopeptides; Lipopolysaccharides; Male; Pandemics; Pneumonia; Pneumonia, Viral; Rats; SARS-CoV-2; Signal Transduction; Thrombin; Toll-Like Receptors | 2020 |
[Antiviral effects of the combination of glycyrrhizin and ribavirin against influenza A H1N1 virus infection in vivo].
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Glycyrrhizic Acid; Inflammation; Influenza A Virus, H1N1 Subtype; Interleukin-1beta; Interleukin-6; Lung; Mice; Orthomyxoviridae Infections; Pneumonia, Viral; Ribavirin; Tumor Necrosis Factor-alpha | 2015 |